PCYT1A

Across TCGA pan-cancer cohorts, PCYT1A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PCYT1A data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PCYT1A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCYT1A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, SKCM, and UCEC are the cancer types where PCYT1A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.211	0.627	.015	30	view →
SKCM	DFS	Median	All	0.232	0.646	.002	16	view →
UCEC	DFS	Median	All	1.000	0.626	.028	8	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.023	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PCYT1A–BLCA (DFS)

Open the BLCA breakdown →